sulfasalazine has been researched along with Local Neoplasm Recurrence in 3 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0." | 7.01 | The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021) |
| " Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0." | 3.01 | The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021) |
| "The patient was diagnosed with reactive arthritis associated with BCG intravesical injection therapy, as three typical symptoms were observed (bilateral conjunctivitis, urethritis, polyarthritis)." | 1.72 | [A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine]. ( Endo, T; Ishitsuka, R; Kinase, S; Oguni, H; Takahashi, R; Tsutsumi, M; Yanagihashi, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Louis, E | 1 |
| Paridaens, K | 1 |
| Al Awadhi, S | 1 |
| Begun, J | 1 |
| Cheon, JH | 1 |
| Dignass, AU | 1 |
| Magro, F | 1 |
| Márquez, JR | 1 |
| Moschen, AR | 1 |
| Narula, N | 1 |
| Rydzewska, G | 1 |
| Freddi, MJ | 1 |
| Travis, SP | 1 |
| Takahashi, R | 1 |
| Kinase, S | 1 |
| Yanagihashi, R | 1 |
| Ishitsuka, R | 1 |
| Endo, T | 1 |
| Oguni, H | 1 |
| Tsutsumi, M | 1 |
| Zhao, J | 1 |
| Zhou, W | 1 |
| Wu, Y | 1 |
| Ji, P | 1 |
| Yang, L | 1 |
| Yan, X | 1 |
| Zhang, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy, Safety and Cost-effectiveness of Hydroxychloroquine, Sulfasalazine, Methotrexate Triple Therapy in Preventing Relapse Among Patients With Rheumatoid Arthritis Achieving Clinical Remission or Low Disease Activity[NCT02320630] | 240 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sulfasalazine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Human | 2021 |
2 other studies available for sulfasalazine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerat | 2022 |
[A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine].
Topics: Administration, Intravesical; Aged; Arthritis, Reactive; BCG Vaccine; Carcinoma, Transitional Cell; | 2022 |